NEXI
Price:
$0.371
Market Cap:
$711.28K
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted...[Read more]
Industry
Biotechnology
IPO Date
2021-02-12
Stock Exchange
NASDAQ
Ticker
NEXI
According to NexImmune, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.02. This represents a change of -90.21% compared to the average of -0.20 of the last 4 quarters.
The mean historical PE Ratio of NexImmune, Inc. over the last ten years is -15.48. The current -0.02 PE Ratio has changed -87.08% with respect to the historical average. Over the past ten years (40 quarters), NEXI's PE Ratio was at its highest in in the March 2023 quarter at 0.01. The PE Ratio was at its lowest in in the December 2019 quarter at -19.98.
Average
-15.48
Median
-10.13
Minimum
-44.45
Maximum
0.01
Discovering the peaks and valleys of NexImmune, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = 0.01
Minimum Annual Increase = -732.99%
Minimum Annual PE Ratio = -44.45
Year | PE Ratio | Change |
---|---|---|
2023 | -0.07 | -732.99% |
2022 | 0.01 | -100.56% |
2021 | -2.03 | -88.84% |
2020 | -18.22 | -35.17% |
2019 | -28.10 | -36.78% |
The current PE Ratio of NexImmune, Inc. (NEXI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.70
5-year avg
-9.68
10-year avg
-15.48
NexImmune, Inc.’s PE Ratio is greater than ZyVersa Therapeutics, Inc. (-0.10), greater than Palisade Bio, Inc. (-0.31), greater than Unicycive Therapeutics, Inc. (-0.46), greater than Apexigen, Inc. (-0.36), greater than Immix Biopharma, Inc. (-2.98), greater than TransCode Therapeutics, Inc. (-0.10), greater than Landos Biopharma, Inc. (-5.74), greater than Oncorus, Inc. (-0.04), greater than Xenetic Biosciences, Inc. (-1.29), less than eFFECTOR Therapeutics, Inc. (-0.00), greater than Virios Therapeutics, Inc. (-0.87), greater than Zura Bio Limited (-9.00), less than Navidea Biopharmaceuticals, Inc. (0.03), less than CNS Pharmaceuticals, Inc. (-0.00), greater than Sonnet BioTherapeutics Holdings, Inc. (-0.55), greater than Mereo BioPharma Group plc (-18.18), greater than Terns Pharmaceuticals, Inc. (-6.06), greater than PDS Biotechnology Corporation (-2.64), greater than Inozyme Pharma, Inc. (-3.48), greater than HOOKIPA Pharma Inc. (-1.22),
Company | PE Ratio | Market cap |
---|---|---|
-0.10 | $2.70M | |
-0.31 | $4.25M | |
-0.46 | $33.41M | |
-0.36 | $9.57M | |
-2.98 | $54.08M | |
-0.10 | $4.56M | |
-5.74 | $71.68M | |
-0.04 | $3.14M | |
-1.29 | $6.06M | |
-0.00 | $188.18K | |
-0.87 | $4.94M | |
-9.00 | $230.86M | |
0.03 | $100.08K | |
-0.00 | $4.60M | |
-0.55 | $4.53M | |
-18.18 | $664.26M | |
-6.06 | $549.60M | |
-2.64 | $107.88M | |
-3.48 | $312.42M | |
-1.22 | $159.50M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NexImmune, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NexImmune, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is NexImmune, Inc.'s PE Ratio?
How is the PE Ratio calculated for NexImmune, Inc. (NEXI)?
What is the highest PE Ratio for NexImmune, Inc. (NEXI)?
What is the 3-year average PE Ratio for NexImmune, Inc. (NEXI)?
What is the 5-year average PE Ratio for NexImmune, Inc. (NEXI)?
How does the current PE Ratio for NexImmune, Inc. (NEXI) compare to its historical average?